A changing paradigm in the management of patients with severe aortic stenosis, transcatheter aortic valve replacement (TAVR) is a minimally invasive, catheter-based procedure to replace the aortic valve. Prior to TAVR, treatment options were limited to:
TAVR does not require open-heart surgery. Instead, with TAVR, the heart is accessed via an artery. There are three access options:
Using imaging and a delivery system, the physician threads the compressed bioprosthetic heart valve through the catheter and positions it within the diseased valve.
After positioning the bioprosthetic valve, the physician begins deploying the valve; the middle image below shows a partially expanded valve. When deployment is complete, the bioprosthetic valve is fully expanded within the diseased native valve.
After testing the new valve function, the physician removes the catheter and closes the incision.
TAVR may be an excellent option for certain patients with severe symptomatic aortic stenosis who may have increased risks associated with surgical aortic valve implantation (SAVI).1
Without intervention, this patient population's survival rate is approximately 50% at two years.2
The Evolut™ TAVR Platform is the only TAVR platform on the market to demonstrate statistically significant better outcomes in terms of all cause mortality or stroke at 3 years vs. SAVR.3
The Evolut TAVR platform’s supra-annular valve design delivers large EOAs (effective orifice area) and low single-digit gradients resulting in industry-leading hemodynamics.
Most medical procedures have risks. The Medtronic TAVR procedure’s most serious risks include:
Today, TAVR is a proven procedure that can prolong lives. At Medtronic, we believe it is the choice for patients who can return to an active life.
We've designed the Evolut platform to achieve industry-leading hemodynamics, which are important to younger, more active patients.
We offer outstanding training and resources for your heart teams.
Schwartz F, et al. Circulation. 1982; 66:1105-1110.
Lester SJ, Heilbron B, Gin K, Dodek A, Jue J. The natural history and rate of progression of aortic stenosis. Chest. 1998 Apr;113(4):1109-14. Review. PubMed PMID: 9554654.
Deeb GM, et al, J Am Coll Cardiol. 2016 Jun 7;67(22):2565-74. doi: 10.1016/j.jacc.2016.03.506. Epub 2016 Apr 3.